user avatar
Rita Redberg
@RFRedberg
UCSF cardiologist. NYC born and bred. Avid cyclist. Working to make needed health care accessible and affordable for all.
San Francisco
Joined July 2011
Posts
  • user avatar
    Many millions have taken statins > 40 yrs and costing $$ trillions. Yet, there still is no randomized trial showing that healthy people live longer or feel better with statins, and many suffer from taking them. Time for an RCT, we cannot afford NOT to have high quality evidence.
  • user avatar
    Fundamental problems when “Ninety percent of C-sections are unnecessary; 80% of stents are inappropriate; 30% of people with cancer get the wrong treatment,” We need a change in the culture of medicine and to move away from the perverse incentives of fee-for-service.
    It's not just prices. Unnecessary tests and procedures are performed every day in America's hospitals and physician offices. modernhealthcare.com/article/201902… via @modrnhealthcr
  • user avatar
    Many authors of commentaries on RCTs of CV interventions, e.g.PCI, had financial ties w/the sponsor. 96% of these authors had undisclosed financial ties. We call on fellow journal editors to invite commentaries w/o conflict of interest. ja.ma/2Wf5pu9 @JAMAInternalMed
  • user avatar
    Another high quality randomized trial showing no reduction in heart attacks and no mortality benefit with stents in high-risk patients. One cannot rely on quality of life data on subjective endpoints, like angina in an unblinded procedural trial, could all be placebo effect.
    Stents and bypass surgery are no more effective than drug treatment and better health habits in preventing heart attacks and death, a study found on.wsj.com/2qYH2Rw
  • user avatar
    FDA needs to stop approving, payers should not cover and doctors shouldn’t recommend devices for patients, unless there is high quality data of net benefit! Change needed now. Don’t Put That in My Heart Until You’re Sure It Really Works @NYTimes
  • user avatar
    thank you. I am so touched and humbled and honored. It was truly a joy every day, and a great privilege to lead JAMA IM, I learned so much from all of our editors, ed board, reviewers and authors. The Rita Redberg Era at JAMA Internal Medicine
  • user avatar
    @RFRedberg is a recipient of the @PennMedicine 2021 Perelman School of Medicine Distinguished Graduate Award, 🏆 honoring #alumni for their outstanding service to society, medicine and accomplishments in #research, practice and #education. tiny.ucsf.edu/QS4XIj
  • user avatar
    Study finds patients are not being informed about harms of CT for lung cancer screening. We need to do better. Failing Grade for Shared Decision Making for Lung Cancer Screening ja.ma/2KPrRyg
  • user avatar
    even in the highest lung cancer risk quintile, the number needed to screen is 552! important to inform patients before when discussing risks and benefits of a CT scan. Reducing Harms in Lung Cancer Screening ja.ma/2DYQmr2
  • user avatar
    In my practice, no patient has ever complained to me about suffering from a high BNP. But they do appreciate being able to walk more.
    PARALLAX trial of Entresto in 2572 patients with HFpEF (EF>40%) Entresto reduced NT-proBNP at 12 weeks but not 6 min walk time at 24weeks Is the overall data now still consistent with FDA decision for use in HFpEF ? @kaulcsmc @CMichaelGibson @djc795 ja.ma/3nlH7cX
  • user avatar
    Very disturbing data revealed on @BBCNewsnight -important results on rates of myocardial infarction in EXCEL trial were not published with the 3 year EXCEL data. Cardiology Guidelines for PCI changed on the basis of that trial. Data transparency is a critical patient safety issue
    STATEMENT – EACTS responds to @BBCNewsnight's investigation into EXCEL Click below to read the full statement. eacts.org/eacts-responds…
  • user avatar
    Replying to @BillsFanPAdashC
    Exactly. It is not evidence- based.
  • user avatar
    I find it remarkable and disappointing that one would do a trial of  taking people with CAD off their meds! I see no reason to ask this question and am surprised it would get IRB approval.  It is not a relevant clinical question.
    ORBITA-2 ⁉️PCI vs placebo in stable CAD w/no-little antianginal meds 🌎 301 pts, 12 weeks FU 🎯 PCI improved angina score+frequency (assessed daily by app 📱), exercise time, CCS and QoL 💔 NO difference in antianginal medications, but still high residual symptoms #AHA23 @NEJM
  • user avatar
    CAC scans offer no clinical benefits, often lead to more tests and worry, incidental findings and radiation risk. Need to rethink their use. Time for an RCT!
    Incremental Value of a Coronary Artery Calcium Score ja.ma/3vbbNkR via @JAMAInternalMed part of @JAMANetwork